5,118 followers
New Research: Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis: Background Sugemalimab is a newly developed inhibitor of programmed death ligand 1… https://t.co/fkew7lwrVc #PublicHealt